Novel genomic variants influencing methotrexate delayed clearance in pediatric patients with acute lymphoblastic leukemia

BackgroundMethotrexate (MTX) is the primary drug used in the treatment of pediatric acute lymphoblastic leukemia (ALL). However, some patients exhibit delayed clearance of high-dose (HD) MTX, which induces severe nephrotoxicity, mucositis, hepatotoxicity, and neurotoxicity. We sought to identify rel...

Olles dieđut

Bibliográfalaš dieđut

Váldodahkkit:	Jung Yoon Choi, Hoshik Kwon, Hyery Kim, Kyung Taek Hong, Youngeun Ma, Kyung-Nam Koh, Sunmin Yun, Keon Hee Yoo, Sang Hoon Song, Ho Joon Im, Ju Han Kim, Hyoung Jin Kang
Materiálatiipa:	Artigo
Giella:	Inglês
Almmustuhtton:	Frontiers Media S.A. 2024-11-01
Ráidu:	Frontiers in Pharmacology
Fáttát:	methotrexate children acute lymphoblastic leukemia pediatric pharmacogenomics adverse reactions
Liŋkkat:	https://www.frontiersin.org/articles/10.3389/fphar.2024.1480657/full
Fáddágilkorat:	Lasit fáddágilkoriid Eai fáddágilkorat, Lasit vuosttaš fáddágilkora!